What's new

Human medicines European public assessment report (EPAR): Omlyclo, omalizumab, Date of authorisation: 16/05/2024, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Omlyclo, omalizumab, Date of authorisation: 16/05/2024, Revision: 2, Status: Authorised

Feb 27, 2025 - 14:05
 0
Human medicines European public assessment report (EPAR): Omlyclo, omalizumab, Date of authorisation: 16/05/2024, Revision: 2, Status: Authorised
Human medicines European public assessment report (EPAR): Omlyclo, omalizumab, Date of authorisation: 16/05/2024, Revision: 2, Status: Authorised
Read More

Tags:

Previous Article

Siemens Mobility advances net zero goals at Goole Rail Village

Next Article

Walgreens Boots buyout to lay groundwork for three-way split of group

Related Posts

Cancer Medicines Forum: December 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, 16 December 2024

Cancer Medicines Forum: December 2024, Online, European...

Mar 11, 2025  0

Human medicines European public assessment report (EPAR): Paxneury, guanfacine, Date of authorisation: 26/02/2025, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 11, 2025  0

Human medicines European public assessment report (EPAR): Ozempic, semaglutide, Date of authorisation: 08/02/2018, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 13, 2025  0